Skip to main content

Kura Oncology, Inc 8-K, filed Nov 10, 2026

Kura Oncology, Inc. (KURA)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Kura Oncology, Inc filed this 8-K on November 10, 2026.

Kura Oncology reported third-quarter KOMZIFTI net product revenue of $13.9 million, up 53% sequentially. The company held $492.1 million in cash, cash equivalents and short-term investments and secured financing capacity of up to $300 million from Oberland Capital. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits